Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Davinci Bio Inc. operates in the Biotechnology & Pharmaceuticals technology area with a focused patenting strategy. The portfolio currently has 1 pending office action in 1 distinct art unit. This indicates a narrow technical focus for the company's current prosecution efforts.
POHNERT, STEVEN C is the 1 distinct examiner involved, accounting for the 1 busiest examiner pending action. Because the entire pending docket is handled by a single examiner, the prosecution process is highly centralized. This structure means that the entity's current patenting success is tied to a single set of examiner reviews.
Practitioners should focus on the specific procedural and technical preferences of the assigned examiner. Because the entire pending portfolio is subject to a single individual's review, the strategy must be precisely calibrated to that examiner's standards. This high level of concentration simplifies docket management but increases the importance of each filing.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POHNERT, STEVEN C | 1 | 12.4% | +18.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16918958 | HIGH CAPACITY MOLECULE DETECTION | POHNERT, STEVEN C | 202d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16918958 | HIGH CAPACITY MOLECULE DETECTION | POHNERT, STEVEN C | 202d overdue |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16918958 | HIGH CAPACITY MOLECULE DETECTION | POHNERT, STEVEN C | 1683 | §102§103§112 | Final Rejection | 202d overdue | Pending | Jul 01, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial